Clinical Trial: A Study of DXC018 in Patients With Advanced Solid Tumors

U.S., Oct. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07849218) titled 'A Study of DXC018 in Patients With Advanced Solid Tumors' on Sept. 22.

Brief Summary: This is a phase I, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, MTD, DLT, RP2D, the PK characteristics, preliminary anti-tumor activity, the immunogenicity of DXC018 in participants with Advanced Solid Tumors.

Study Start Date: Oct. 18

Study Type: INTERVENTIONAL

Condition: Advanced Solid Tumors

Intervention: DRUG: DXC018

Cohort A: Once every 2 weeks (Q2W) with a cycle length of 14 days. Cohort B: Once every 3 weeks (Q3W) with a cycle length of 21 days.

Recruitment Status: NOT_YET_RECRUITING

Sponso...